Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis

Figures & data

Table 1 Summary of peginesatide studies in non dialysis requiring CKD patients

	PEARL 1			PEARL 2
	Peginesatide 0.04 mg/kg	Peginesatide 0.025 mg/kg	Darbepoetin 0.75 μg/kg	Peginesatide 0.04 mg/kg	Peginesatide 0.025 mg/kg	Darbepoetin 0.75 μg/kg
Patients (n)	165	161	164	163	167	163
Change in Hb g/dL* (mean ± SD)	1.39 ± 0.87	1.64 ± 0.97	1.37 ± 0.86	1.50 ± 0.90	1.68 ± 0.96	1.35 ± 1.00
Difference in Hb versus darbepoetin group, mean (97.5% CI)**	0.03 (−0.19.6 to 0.26)	0.26 (0.04–0.48)		0.14 (−0.09 to 0.36)	0.31 (0.08 to 0.54)
Transfusion (% of patients)	6.2%	7.3%	4.9%	11.4%	10.4%	4.9%

Notes:

* Changes in Hb levels from baseline to mean level during 12-week evaluation period;

** noninferiority criteria.

Abbreviations: CI, confidence interval; Hb, hemoglobin; SD, standard deviation; CKD, chronic kidney disease.

Table 2 Summary of peginesatide studies dialysis requiring CKD patients

	EMERALD 1		EMERALD 2
	Peginesatide group	Epoetin group	Peginesatide group	Epoetin group
Patients (n)	445	248	488	237
Change in Hb, g/dL* (mean ± SD)	−0.24 ± 0.96	−0.09 ± 0.92	−0.07 ± 1.01	−0.17 ± 1.00
Difference in Hb versus epoetin group, mean (95% CI)**	−0.15 (−0.30 to −0.01)		0.10 (−0.05 to 0.26)
Transfusion (% of patients)	10.3%	8.6%	7.7%	9.9%

Notes:

* Changes in Hb levels from baseline to mean level during the 12-week evaluation period;

** noninferiority criteria.

Abbreviations: CI, confidence interval; Hb, hemoglobin; SD, standard deviation; CKD, chronic kidney disease.